These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21782770)

  • 21. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reasons for proton-pump-inhibitor failure in the treatment of gastroesophageal reflux disease].
    Juhász M; Tulassay Z
    Orv Hetil; 2008 Oct; 149(40):1881-8. PubMed ID: 18815107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease.
    Hershcovici T; Jha LK; Gadam R; Cui H; Gerson L; Thomson S; Fass R
    J Clin Gastroenterol; 2012 Sep; 46(8):662-8. PubMed ID: 22858518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease.
    Shi YC; Cai ST; Tian YP; Zhao HJ; Zhang YB; Chen J; Ren RR; Luo X; Peng LH; Sun G; Yang YS
    Genomics Proteomics Bioinformatics; 2019 Feb; 17(1):52-63. PubMed ID: 31028880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
    Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Yadlapati R; DeLay K
    Med Clin North Am; 2019 Jan; 103(1):15-27. PubMed ID: 30466671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey.
    Goh KL; Choi MG; Hsu WP; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Chu R; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Gastroenterol Hepatol; 2014 Dec; 29(12):1969-75. PubMed ID: 24990817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
    Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
    Rohof WO; Bennink RJ; de Jonge H; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1647-55. PubMed ID: 24184737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
    El-Serag HB; Fitzgerald S; Richardson P
    Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Guidelines for the treatment of gastroesophageal reflux disease].
    Lee JH; Cho YK; Jeon SW; Kim JH; Kim NY; Lee JS; Bak YT;
    Korean J Gastroenterol; 2011 Feb; 57(2):57-66. PubMed ID: 21350318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
    van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
    Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
    Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
    Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
    El-Serag HB; Wieman M; Richardson P
    Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.